Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
20.34
-0.92 (-4.33%)
Jun 16, 2025, 4:00 PM - Market closed
Celldex Therapeutics Analyst Ratings
Total Analysts
9
Consensus Rating
Buy
Price Target
$50.00
Upside
+145.82%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +145.82% | Jun 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +145.82% | Jun 13, 2025 |
| UBS | UBS | Strong Buy Maintains $44 → $38 | Strong Buy | Maintains | $44 → $38 | +86.82% | May 9, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $36 → $31 | Hold | Maintains | $36 → $31 | +52.41% | May 9, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $46 → $43 | Buy | Maintains | $46 → $43 | +111.41% | May 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $50 | Strong Buy | Maintains | $80 → $50 | +145.82% | May 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +293.31% | May 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $64 | Strong Buy | Initiates | $64 | +214.65% | Apr 28, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $46 | Buy | Initiates | $46 | +126.16% | Mar 20, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $42 → $36 | Hold | Maintains | $42 → $36 | +76.99% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +293.31% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +293.31% | Feb 28, 2025 |
| UBS | UBS | Strong Buy Initiates $44 | Strong Buy | Initiates | $44 | +116.32% | Feb 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $67 | Buy | Reiterates | $67 | +229.40% | Jan 29, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $67 | Buy | Reiterates | $67 | +229.40% | Jan 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +293.31% | Dec 20, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.